These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1373347)

  • 1. IGF binding protein 3 in patients with Laron type dwarfism: effect of exogenous rIGF-I.
    Laron Z; Klinger B; Blum WF; Silbergeld A; Ranke MB
    Clin Endocrinol (Oxf); 1992 Mar; 36(3):301-4. PubMed ID: 1373347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment of Laron type dwarfs with insulin-like growth factor-1 increases serum insulin-like growth factor-binding protein-3 in the absence of growth hormone activity.
    Kanety H; Karasik A; Klinger B; Silbergeld A; Laron Z
    Acta Endocrinol (Copenh); 1993 Feb; 128(2):144-9. PubMed ID: 7680834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone and insulin-like growth factor regulate insulin-like growth factor-binding protein-1 in Laron type dwarfism, growth hormone deficiency and constitutional short stature.
    Laron Z; Suikkari AM; Klinger B; Silbergeld A; Pertzelan A; Seppälä M; Koivisto VA
    Acta Endocrinol (Copenh); 1992 Oct; 127(4):351-8. PubMed ID: 1280392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone insensitivity syndromes: a preliminary report on changes in insulin-like growth factors and their binding proteins during treatment with recombinant insulin-like growth factor I. Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes.
    Blum WF; Hall K; Ranke MB; Wilton P
    Acta Paediatr Suppl; 1993 Sep; 82 Suppl 391():15-9. PubMed ID: 7693071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism.
    Laron Z; Klinger B; Jensen LT; Erster B
    Clin Endocrinol (Oxf); 1991 Aug; 35(2):145-50. PubMed ID: 1934530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of recombinant human insulin-like growth factor-I treatment on growth hormone secretion in two subjects with growth hormone insensitivity (Laron syndrome).
    Cotterill AM; Camacho-Hübner C; Holly JM; Savage MO
    Clin Endocrinol (Oxf); 1993 Jul; 39(1):119-22. PubMed ID: 7688671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of exogenous insulin-like growth factor I on insulin-like growth factor binding proteins in a case of growth hormone insensitivity (Laron-type).
    Gourmelen M; Perin L; Binoux M
    Acta Paediatr Scand Suppl; 1991; 377():115-7. PubMed ID: 1723834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome). Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes.
    Wilton P
    Acta Paediatr Suppl; 1992 Sep; 383():137-42. PubMed ID: 1281024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome.
    Klinger B; Jensen LT; Silbergeld A; Laron Z
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):423-9. PubMed ID: 8959080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The insulin-like growth factor (IGF)-binding proteins and IGF bioactivity in Laron-type dwarfism.
    Cotterill AM; Holly JM; Taylor AM; Davies SC; Coulson VJ; Preece MA; Wass JA; Savage MO
    J Clin Endocrinol Metab; 1992 Jan; 74(1):56-63. PubMed ID: 1370165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of insulin-like growth factor (IGF)-I on serum IGF-I, IGF-binding protein-3 and acid labile subunit in Laron syndrome patients with normal growth hormone binding protein.
    Kanety H; Silbergeld A; Klinger B; Karasik A; Baxter RC; Laron Z
    Eur J Endocrinol; 1997 Dec; 137(6):626-30. PubMed ID: 9437227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum GH binding protein activities identifies the heterozygous carriers for Laron type dwarfism.
    Laron Z; Klinger B; Erster B; Silbergeld A
    Acta Endocrinol (Copenh); 1989 Oct; 121(4):603-8. PubMed ID: 2800930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism.
    Laron Z; Klinger B; Erster B; Anin S
    Lancet; 1988 Nov; 2(8621):1170-2. PubMed ID: 2903379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laron syndrome due to a post-receptor defect: response to IGF-I treatment.
    Laron Z; Klinger B; Eshet R; Kaneti H; Karasik A; Silbergeld A
    Isr J Med Sci; 1993 Dec; 29(12):757-63. PubMed ID: 8300382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levels of growth hormone, insulin-like growth factor-I (IGF-I) and -II, IGF-binding protein-1 and -3, and cortisol in prednisone-treated children with growth retardation after renal transplantation.
    Hokken-Koelega AC; Stijnen T; de Muinck Keizer-Schrama SM; Blum WF; Drop SL
    J Clin Endocrinol Metab; 1993 Oct; 77(4):932-8. PubMed ID: 7691864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laron-type dwarfism with apparently normal high affinity serum growth hormone-binding protein.
    Buchanan CR; Maheshwari HG; Norman MR; Morrell DJ; Preece MA
    Clin Endocrinol (Oxf); 1991 Aug; 35(2):179-85. PubMed ID: 1934534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGF-I and IGF-binding protein-3 in plasma of GH-deficient rats.
    Butler AA; Gallaher BW; Ambler GR; Gluckman PD; Breier BH
    J Endocrinol; 1996 Jul; 150(1):67-76. PubMed ID: 8708564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome).
    Savage MO; Blum WF; Ranke MB; Postel-Vinay MC; Cotterill AM; Hall K; Chatelain PG; Preece MA; Rosenfeld RG
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1465-71. PubMed ID: 7505286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure to increase insulin-like growth factor-I synthesis is involved in the mechanisms of growth retardation of children with inherited liver disorders.
    Maghnie M; Barreca A; Ventura M; Tinelli C; Ponzani P; De Giacomo C; Maggiore G; Severi F
    Clin Endocrinol (Oxf); 1998 Jun; 48(6):747-55. PubMed ID: 9713564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum prolactin in patients with Laron-type dwarfism: effect of insulin-like growth factor I.
    Silbergeld A; Klinger B; Schwartz H; Laron Z
    Horm Res; 1992; 37(4-5):160-4. PubMed ID: 1490658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.